Straits Times Index
3,323.18 +9.04 (+0.27%) Nikkei
39,098.11 +293.46 (+0.76%) Hang Seng
18,139.89 +112.18 (+0.62%) FTSE 100
8,281.55 +43.83 (+0.53%) Bitcoin USD
61,112.98 -1,281.46 (-2.05%) CMC Crypto 200
1,273.99 -35.73 (-2.73%)
LXRX Oct 2024 1.000 call
| Previous close | 1.0500 |
| Open | 1.0500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.00 |
| Expiry date | 2024-10-18 |
| Day's range | 1.0500 - 1.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireLexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and Potential Launch in Early 2025 THE WOODLANDS, Texas, June 21, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following multiple interactions with and recent feedback from the U.S. Food and Drug Administration (FDA), it has resubmitted its New Drug Application
- GlobeNewswire
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators conclude that clinical outcomes of RELIEF-DPN 1 support commencement of Lexicon’s dose-ranging Phase 2b PROGRESS trial, currently enrolling patients THE WOODLANDS, Texas, June 19, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diabetes Care, the peer-revie
- GlobeNewswire
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness Research THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA® (sotagliflozin) is cost-effective for pe
